Back
Status filter :


RESET SEARCH AND FILTERS
Respiratory system
Respiratory system / Respiratory depression, respiratory distress syndrome and apnoea
  doxapram hydrochloride Hospital only
  Solution for injection
Doxapram hydrochloride (Non-proprietary) Hospital only
Respiratory system / Airways disease, obstructive
  aclidinium bromide Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Eklira (Covis Pharma GmbH) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  aclidinium bromide with formoterol Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Duaklir (Covis Pharma GmbH) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  aminophylline Specialist knowledge/initiation
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  Solution for injection
Aminophylline (Non-proprietary) Hospital only
  beclometasone dipropionate Joint formulary choice
  Modified-release tablet
Clipper (Chiesi Ltd)
  Pressurised inhalation
Beclu (Lupin Healthcare (UK) Ltd)
Clenil Modulite (Chiesi Ltd)
Kelhale (Cipla EU Ltd)
Qvar (Teva UK Ltd)
Qvar Autohaler (Teva UK Ltd)
Qvar Easi-Breathe (Teva UK Ltd)
Soprobec (Glenmark Pharmaceuticals Europe Ltd)
  Inhalation powder
Easyhaler (Orion Pharma (UK) Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Spray
Beclometasone dipropionate (Non-proprietary)
Beconase (GlaxoSmithKline UK Ltd, Omega Pharma Ltd)
Nasobec (Teva UK Ltd)
  Cutaneous ointment
Beclometasone dipropionate (Non-proprietary)
  Cutaneous cream
Beclometasone dipropionate (Non-proprietary)
  beclometasone with formoterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Pressurised inhalation
Beclometasone with formoterol (Non-proprietary)
Bibecfo (Cipla EU Ltd)
Fostair (Chiesi Ltd)
Luforbec (Lupin Healthcare (UK) Ltd)
  Inhalation powder
Fostair NEXThaler (Chiesi Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  beclometasone with formoterol and glycopyrronium Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Joint Prescribing Group (JPG) decision

February 2018 - The JPG agreed to approve the addition of Trimbow® (beclometasone with formoterol and glycopyrronium combination inhaler) to the Joint Formulary.

Trimbow® can be used as an alternative for patients requiring triple therapy with Fostair® (beclometasone 100mcg/formoterol 6mcg - 2 doses twice daily) AND SeeBri® (glycopyrronium 44mcg - 1 dose once daily) 

  Pressurised inhalation
Trimbow (Chiesi Ltd)
  Inhalation powder
Trimbow NEXThaler (Chiesi Ltd)
  benralizumab Non-formulary at HHFT and not suitable for primary care prescribing NICE TA565
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Solution for injection
Fasenra (AstraZeneca UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  budesonide Joint formulary choice NICE TA708
NICE TA937
  Orodispersible tablet
Jorveza (Dr. Falk Pharma UK Ltd)
  Modified-release tablet
Cortiment (Ferring Pharmaceuticals Ltd)
  Modified-release capsule
Budesonide (Non-proprietary)
Kinpeygo (Genus Pharmaceuticals Holdings Ltd)
  Gastro-resistant capsule
Budenofalk (Dr. Falk Pharma UK Ltd)
  Gastro-resistant granules
Budenofalk (Dr. Falk Pharma UK Ltd)
  Inhalation powder
Budelin Novolizer (Viatris UK Healthcare Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Easyhaler (Orion Pharma (UK) Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Pulmicort Turbohaler (AstraZeneca UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Nebuliser liquid
Budesonide (Non-proprietary) Specialist knowledge/initiation
Pulmicort Respules (AstraZeneca UK Ltd) Specialist knowledge/initiation
  Enema
Entocort (Tillotts Pharma UK Ltd)
  Spray
Budesonide (Non-proprietary)
  Rectal foam
Budenofalk (Dr. Falk Pharma UK Ltd)
  budesonide with formoterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Pressurised inhalation
Symbicort (AstraZeneca UK Ltd)
  Inhalation powder
DuoResp Spiromax (Teva UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Fobumix Easyhaler (Orion Pharma (UK) Ltd) Not approved for prescribing
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Symbicort Turbohaler (AstraZeneca UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

WockAIR (Wockhardt UK Ltd)
  ciclesonide Not approved for prescribing
  Pressurised inhalation
Alvesco (Covis Pharma GmbH)
  dupilumab Non-formulary at HHFT and not suitable for primary care prescribing NICE TA534
NICE TA751
NICE TA955
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Solution for injection
Dupixent (Sanofi) Non-formulary at HHFT and not suitable for primary care prescribing
  ephedrine hydrochloride Not approved for prescribing
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  Solution for injection
Ephedrine hydrochloride (Non-proprietary)
  Oral tablet
Ephedrine hydrochloride (Non-proprietary)
  fluticasone Joint formulary choice
  Pressurised inhalation
Flixotide Evohaler (GlaxoSmithKline UK Ltd)
  Inhalation powder
Flixotide Accuhaler (GlaxoSmithKline UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Spray
Fluticasone (Non-proprietary)
Avamys (GlaxoSmithKline UK Ltd)
Coryen (Alissa Healthcare Research Ltd)
Flixonase (GlaxoSmithKline UK Ltd, Haleon UK Trading Ltd)
Nasofan (Teva UK Ltd)
  Nasal drops
Fluticasone (Non-proprietary)
  Cutaneous ointment
Cutivate (GlaxoSmithKline UK Ltd)
  Cutaneous cream
Fluticasone (Non-proprietary)
  fluticasone with formoterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Pressurised inhalation
Flutiform (Napp Pharmaceuticals Ltd)
  fluticasone with salmeterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Pressurised inhalation
AirFluSal (Sandoz Ltd)
Aloflute (Viatris UK Healthcare Ltd)
Avenor (Zentiva Pharma UK Ltd)
Combisal (Aspire Pharma Ltd)
Sereflo (Cipla EU Ltd)
Seretide Evohaler (GlaxoSmithKline UK Ltd)
Sirdupla (Viatris UK Healthcare Ltd)
  Inhalation powder
AirFluSal Forspiro (Sandoz Ltd) Not approved for prescribing
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Campona Airmaster (Genesis Pharmaceuticals Ltd)
Fixkoh Airmaster (Genus Pharmaceuticals Holdings Ltd)
Fusacomb Easyhaler (Orion Pharma (UK) Ltd)
Sereflo Ciphaler (Cipla EU Ltd)
Seretide Accuhaler (GlaxoSmithKline UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Stalpex (Glenmark Pharmaceuticals Europe Ltd)
  fluticasone with umeclidinium and vilanterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Trelegy Ellipta (GlaxoSmithKline UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  fluticasone with vilanterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Relvar Ellipta (GlaxoSmithKline UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  formoterol fumarate Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Pressurised inhalation
Atimos Modulite (Chiesi Ltd)
  Inhalation powder
Easyhaler (Orion Pharma (UK) Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Oxis Turbohaler (AstraZeneca UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  formoterol fumarate with glycopyrronium and budesonide
  Pressurised inhalation
Formoterol fumarate with glycopyrronium and budesonide (Non-proprietary)
  glycopyrronium bromide Joint formulary choice
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  Solution for injection
Glycopyrronium bromide (Non-proprietary)
  Inhalation powder
Seebri Breezhaler (Novartis Pharmaceuticals UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  glycopyrronium with formoterol fumarate
  Pressurised inhalation
Bevespi Aerosphere (AstraZeneca UK Ltd)
  glycopyrronium with indacaterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Ultibro Breezhaler (Novartis Pharmaceuticals UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  human alpha<sub>1</sub>-proteinase inhibitor Not approved for prescribing
  Powder and solvent for solution for infusion
Respreeza (CSL Behring UK Ltd) Not approved for prescribing
  indacaterol Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Onbrez Breezhaler (Novartis Pharmaceuticals UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  indacaterol with mometasone furoate
  Inhalation powder
Atectura Breezhaler (Novartis Pharmaceuticals UK Ltd)
  ipratropium bromide Joint formulary choice
  Pressurised inhalation
Atrovent (Boehringer Ingelheim Ltd)
Inhalvent (Alissa Healthcare Research Ltd)
  Nebuliser liquid
Ipratropium bromide (Non-proprietary)
Atrovent UDV (Boehringer Ingelheim Ltd)
  Spray
Ipratropium bromide (Non-proprietary)
  ipratropium with salbutamol Not approved for prescribing
  Nebuliser liquid
Combiprasal (TriOn Pharma Ltd)
Combivent (Boehringer Ingelheim Ltd)
Ipramol (Teva UK Ltd)
  mepolizumab Non-formulary at HHFT and not suitable for primary care prescribing NICE TA671
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

Where negative or terminated NICE Technology Appraisal(s) apply to this medicine

This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use.

  Solution for injection
Nucala (GlaxoSmithKline UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  Powder for solution for injection
Nucala (GlaxoSmithKline UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  mometasone furoate Joint formulary choice
  Inhalation powder
Asmanex Twisthaler (Organon Pharma (UK) Ltd) Joint formulary choice
  Spray
Mometasone furoate (Non-proprietary)
Nasonex (Organon Pharma (UK) Ltd)
  Cutaneous ointment
Mometasone furoate (Non-proprietary)
Elocon (Organon Pharma (UK) Ltd)
  Cutaneous cream
Mometasone furoate (Non-proprietary)
Elocon (Organon Pharma (UK) Ltd)
  Cutaneous liquid
Elocon (Organon Pharma (UK) Ltd)
  mometasone furoate with glycopyrronium bromide and indacaterol
  Inhalation powder
Enerzair Breezhaler (Novartis Pharmaceuticals UK Ltd)
  montelukast Joint formulary choice
  Chewable tablet
Montelukast (Non-proprietary) Joint formulary choice
Singulair (Organon Pharma (UK) Ltd) Joint formulary choice
  Oral tablet
Montelukast (Non-proprietary)
Singulair (Organon Pharma (UK) Ltd)
  Oral granules
Montelukast (Non-proprietary)
Singulair (Organon Pharma (UK) Ltd)
  olodaterol Not approved for prescribing
  Inhalation solution
Striverdi Respimat (Boehringer Ingelheim Ltd)
  omalizumab Hospital only NICE TA278
NICE TA339
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

Where negative or terminated NICE Technology Appraisal(s) apply to this medicine

This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use.

  Solution for injection
Xolair (Novartis Pharmaceuticals UK Ltd) Hospital only
Xolair®

The JPG has approved the prescribing of this medicine at accredited specialist hospitals, provided that it is used in accordance to the relevant NICE Technology Appraisal.

  reslizumab Hospital only NICE TA479
Specialist Centre initiation

The Joint Prescribing Group agreed to approve this medicine for use at Homerton University Hospital Foundation Trust, provided it is initiated at a specialist centre and used specifically in accordance with the current relevant NICE Technology Appraisals (TAs).

  Solution for infusion
Cinqaero (Teva UK Ltd) Hospital only
Specialist Centre initiation

The Joint Prescribing Group agreed to approve this medicine for use at Homerton University Hospital Foundation Trust, provided it is initiated at a specialist centre and used specifically in accordance with the current relevant NICE Technology Appraisals (TAs).

  roflumilast Specialist knowledge/initiation NICE TA461
ROFLUMILAST

This medication should be initiated by a specialist in respiratory medicine.

  Oral tablet
Roflumilast (Non-proprietary)
Daxas (AstraZeneca UK Ltd)
  salbutamol Joint formulary choice
Injection/infusion formulations

The injection/infusion formulation of this medicine is not recommended for prescribing in primary care (i.e. hospital only prescribing).

  Solution for injection
Ventolin (GlaxoSmithKline UK Ltd) Hospital only
  Solution for infusion
Ventolin (GlaxoSmithKline UK Ltd) Hospital only
  Pressurised inhalation
Airomir (Teva UK Ltd)
Airomir Autohaler (Teva UK Ltd)
Salamol (Teva UK Ltd)
Salamol Easi-Breathe (Teva UK Ltd)
Ventolin Evohaler (GlaxoSmithKline UK Ltd)
  Inhalation powder
Easyhaler (Orion Pharma (UK) Ltd) Joint formulary choice
Salbulin Novolizer (Viatris UK Healthcare Ltd) Joint formulary choice
Ventolin Accuhaler (GlaxoSmithKline UK Ltd) Joint formulary choice
  Nebuliser liquid
Salbutamol (Non-proprietary)
Brodilaten (Kent Pharma (UK) Ltd)
Ventolin (GlaxoSmithKline UK Ltd)
  salmeterol Joint formulary choice
  Pressurised inhalation
Serevent Evohaler (GlaxoSmithKline UK Ltd)
Soltel (Cipla EU Ltd)
  Inhalation powder
Serevent Accuhaler (GlaxoSmithKline UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  terbutaline sulfate Joint formulary choice
  Solution for injection
Bricanyl (AstraZeneca UK Ltd) Hospital only
  Inhalation powder
Bricanyl Turbohaler (AstraZeneca UK Ltd) Joint formulary choice
  Nebuliser liquid
Terbutaline sulfate (Non-proprietary)
Bricanyl Respules (AstraZeneca UK Ltd)
  Oral tablet
Bricanyl (AstraZeneca UK Ltd)
  tezepelumab Non-formulary at HHFT and not suitable for primary care prescribing NICE TA880
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Solution for injection
Tezspire (AstraZeneca UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  theophylline Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Modified-release tablet
Uniphyllin Continus (Ennogen Healthcare Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  tiotropium Joint formulary choice
TIOTROPIUM

Braltus Zonda® 10 micrograms inhalation powder is bioequivalent to Tiotropium Handihaler® 18 micrograms. Braltus Zonda® is the formulary choice tiotropium inhalation powder for initiation in new patients. 

Click here to access the SPC for Braltus Zonda® 10 micrograms inhalation powder

Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Acopair (Viatris UK Healthcare Ltd)
Braltus (Teva UK Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Spiriva (Boehringer Ingelheim Ltd) Joint formulary choice
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Tiogiva (Glenmark Pharmaceuticals Europe Ltd)
  Inhalation solution
Spiriva Respimat (Boehringer Ingelheim Ltd)
  tiotropium with olodaterol
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation solution
Spiolto Respimat (Boehringer Ingelheim Ltd)
  umeclidinium Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Incruse Ellipta (GlaxoSmithKline UK Ltd) Specialist knowledge/initiation
  umeclidinium with vilanterol Specialist knowledge/initiation
Prescribe by brand

Please prescribe this product by brand to avoid dispensing and administration errors.

Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Inhalation powder
Anoro Ellipta (GlaxoSmithKline UK Ltd) Specialist knowledge/initiation
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

Respiratory system / Cough and congestion
  citric acid Not approved for prescribing
  Oral solution
Citric acid (Non-proprietary) Not approved for prescribing
  codeine phosphate Specialist knowledge/initiation
  Oral solution
Codeine phosphate (Non-proprietary) Specialist knowledge/initiation
Galcodine (Thornton & Ross Ltd) Specialist knowledge/initiation
  Oral tablet
Codeine phosphate (Non-proprietary)
  eucalyptus with menthol Not approved for prescribing
  methadone hydrochloride Hospital only NICE TA114
  Oral solution
Methadone hydrochloride (Non-proprietary) Hospital only
Methadose (Rosemont Pharmaceuticals Ltd) Hospital only
Metharose (Rosemont Pharmaceuticals Ltd) Hospital only
Physeptone (Martindale Pharmaceuticals Ltd) Hospital only
  Solution for injection
Methadone hydrochloride (Non-proprietary) Hospital only
Parenteral methadone

Parenteral methadone should only be prescribed in secondary care by or under the explicit direction of a specialist.

  Oral tablet
Methadone hydrochloride (Non-proprietary)
  morphine Specialist knowledge/initiation
  Orodispersible tablet
Actimorph (Ethypharm UK Ltd)
  Modified-release tablet
MST Continus (Napp Pharmaceuticals Ltd)
Morphgesic SR (Advanz Pharma)
  Modified-release capsule
MXL (Napp Pharmaceuticals Ltd)
Zomorph (Ethypharm UK Ltd)
  Oral solution
Morphine (Non-proprietary) Specialist knowledge/initiation
Oramorph (Glenwood GmbH) Specialist knowledge/initiation
  Solution for injection
Morphine (Non-proprietary)
  Infusion
Morphine (Non-proprietary)
  Solution for infusion
Morphine (Non-proprietary)
  Oral tablet
Sevredol (Napp Pharmaceuticals Ltd)
Respiratory system / Allergic conditions
  BIRCH POLLEN EXTRACT (ITULAZAX) Hospital only
North East London Formulary & Pathways Group’s Decision

February 2023 - The North East London Formulary & Pathways Group (FPG) approved the use of Itulazax in adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. This treatment should only be prescribed by the allergy team.

  acrivastine Not approved for prescribing
  Oral capsule
Acrivastine (Non-proprietary)
Benadryl Allergy Relief (McNeil Products Ltd)
  alimemazine tartrate Not approved for prescribing
  Oral solution
Alimemazine tartrate (Non-proprietary) Not approved for prescribing
Alfresed (Syri Ltd)
Itzenal (Zentiva Pharma UK Ltd)
  Oral tablet
Alimemazine tartrate (Non-proprietary)
  bee venom extract Non-formulary at HHFT and not suitable for primary care prescribing NICE TA246
  bilastine Not approved for prescribing
  Oral tablet
Ilaxten (A. Menarini Farmaceutica Internazionale SRL)
  cetirizine hydrochloride Joint formulary choice
  Oral solution
Cetirizine hydrochloride (Non-proprietary) Joint formulary choice
  Oral tablet
Cetirizine hydrochloride (Non-proprietary) Joint formulary choice
  chlorphenamine maleate Joint formulary choice
  Oral solution
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
Allerief (Crescent Pharma Ltd) Joint formulary choice
Prescribe generically

.

Piriton (Haleon UK Trading Ltd) Joint formulary choice
Prescribe generically

.

  Solution for injection
Chlorphenamine maleate (Non-proprietary) Hospital only
  Oral tablet
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
Allerief (Crescent Pharma Ltd)
Hayleve (Genesis Pharmaceuticals Ltd)
Piriton (Haleon UK Trading Ltd)
  cyproheptadine hydrochloride Not approved for prescribing
  Oral tablet
Periactin (Teva UK Ltd)
  desloratadine Not approved for prescribing
  Oral solution
Desloratadine (Non-proprietary) Not approved for prescribing
Neoclarityn (Organon Pharma (UK) Ltd) Not approved for prescribing
  Oral tablet
Desloratadine (Non-proprietary)
Neoclarityn (Organon Pharma (UK) Ltd)
  fexofenadine hydrochloride Joint formulary choice
  Oral tablet
Fexofenadine hydrochloride (Non-proprietary)
Telfast (Sanofi Consumer Healthcare)
  grass pollen extract Hospital only
  Oral lyophilisate
Grazax (ALK-Abello Ltd) Hospital only
  Form unstated
Pollinex Grasses + Rye (Allergy Therapeutics (UK) Ltd) Hospital only
  house dust mite extract Hospital only
North East London Formulary &amp; Pathways Group&#39;s Decision

December 2022 - The North East London Formulary & Pathways Group (FPG) approved the use of Acarizax® 12 SQ-HDM oral lyophilisates for the management of house dust mite allergic rhinitis in patients 12 years and above. This treatment should only be prescribed by the allergy team.

  Oral lyophilisate
Acarizax (ALK-Abello Ltd) Hospital only
North East London Formulary &amp; Pathways Group&#39;s Decision

December 2022 - The North East London Formulary & Pathways Group (FPG) approved the use of Acarizax® 12 SQ-HDM oral lyophilisates for the management of house dust mite allergic rhinitis in patients 12 years and above. This treatment should only be prescribed by the allergy team.

  hydroxyzine hydrochloride Joint formulary choice
  Oral tablet
Hydroxyzine hydrochloride (Non-proprietary)
  ketotifen Not approved for prescribing
  Oral solution
Zaditen (CD Pharma Srl) Not approved for prescribing
  Eye drops
Ketofall (Scope Ophthalmics Ltd)
Zaditen (Thea Pharmaceuticals Ltd) Not approved for prescribing
  Oral tablet
Zaditen (CD Pharma Srl)
  levocetirizine hydrochloride Not approved for prescribing
  Oral solution
Xyzal (UCB Pharma Ltd) Not approved for prescribing
  Oral tablet
Levocetirizine hydrochloride (Non-proprietary)
Xyzal (UCB Pharma Ltd)
  loratadine Joint formulary choice
  Oral solution
Loratadine (Non-proprietary) Joint formulary choice
  Oral tablet
Loratadine (Non-proprietary) Joint formulary choice
  mizolastine Not approved for prescribing
  Modified-release tablet
Mizollen (Sanofi Consumer Healthcare) Not approved for prescribing
  peanut protein Hospital only
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Form unstated
Palforzia (Stallergenes Greer Ltd) Hospital only
  Oral powder
Palforzia (Stallergenes Greer Ltd)
  promethazine hydrochloride Joint formulary choice
  Oral solution
Phenergan (Sanofi Consumer Healthcare) Joint formulary choice
  Solution for injection
Phenergan (Sanofi Consumer Healthcare) Hospital only
  Oral tablet
Promethazine hydrochloride (Non-proprietary)
Phenergan (Sanofi Consumer Healthcare)
Sominex (Dexcel-Pharma Ltd)
  rupatadine Not approved for prescribing
  Oral tablet
Rupatadine (Non-proprietary)
  tree pollen extract Non-formulary at HHFT and not suitable for primary care prescribing
  Suspension for injection
Pollinex Trees (Allergy Therapeutics (UK) Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  Form unstated
Pollinex Trees (Allergy Therapeutics (UK) Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  wasp venom extract Hospital only NICE TA246
Joint Prescribing Group's decision

January 2020 - the JPG agreed to approve the addition of Alutard SQ® (bee venom and wasp venom suspension for injection) to the joint formulary for the management of Bee allergy. Treatment should be carried out under the supervision of a doctor experienced in specific immunotherapy. 

Respiratory system / Anaphylaxis
  adrenaline/epinephrine Joint formulary choice
Epipen®, Emerade® and Jext® are not used in exactly the same way

Please note different brands of adrenaline auto-injectors are not used in exactly the same way - specific training and advice is required for each of the devices.

  Solution for injection
Adrenaline/epinephrine (Non-proprietary) Hospital only
EpiPen (Viatris UK Healthcare Ltd) Joint formulary choice
Jext (ALK-Abello Ltd) Joint formulary choice
  chlorphenamine maleate Joint formulary choice
  Oral solution
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
Allerief (Crescent Pharma Ltd) Joint formulary choice
Piriton (Haleon UK Trading Ltd) Joint formulary choice
  Solution for injection
Chlorphenamine maleate (Non-proprietary) Hospital only
  Oral tablet
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
Allerief (Crescent Pharma Ltd)
Hayleve (Genesis Pharmaceuticals Ltd)
Piriton (Haleon UK Trading Ltd)
Respiratory system / Angioedema
  C1-esterase inhibitor Hospital only
  Powder and solvent for solution for injection
Berinert P (CSL Behring UK Ltd) Hospital only
Cinryze (Takeda UK Ltd) Hospital only
  berotralstat Non-formulary at HHFT and not suitable for primary care prescribing NICE TA738
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Oral capsule
Orladeyo (BioCryst Ireland Ltd)
  conestat alfa Hospital only
  Powder for solution for injection
Ruconest (Pharming Group N.V.) Hospital only
  Powder and solvent for solution for injection
Ruconest (Pharming Group N.V.)
  icatibant Hospital only
  Solution for injection
Icatibant (Non-proprietary)
Firazyr (Takeda UK Ltd) Hospital only
  lanadelumab Non-formulary at HHFT and not suitable for primary care prescribing NICE TA606
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Solution for injection
Lanadelumab (Non-proprietary)
Takhzyro (Takeda UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
Respiratory system / Conditions affecting sputum viscosity
  acetylcysteine Not approved for prescribing
  Effervescent tablet
Acetylcysteine (Non-proprietary) Not approved for prescribing
A-CYS (Ennogen Healthcare Ltd) Not approved for prescribing
AceCil (Essential-Healthcare Ltd)
Acepiro (Stirling Anglian Pharmaceuticals Ltd)
NACSYS (Alturix Ltd) Not approved for prescribing
  Solution for infusion
Acetylcysteine (Non-proprietary)
Parvolex (Phoenix Labs Ltd)
  Eye drops
Ilube (Rayner Pharmaceuticals Ltd)
  carbocisteine Joint formulary choice
  Oral solution
Carbocisteine (Non-proprietary) Joint formulary choice
Mucodyne (Sanofi) Joint formulary choice
  Oral capsule
Carbocisteine (Non-proprietary)
  erdosteine Not approved for prescribing
  Oral capsule
Erdotin (Galen Ltd)
Respiratory system / Cystic fibrosis
  dornase alfa Non-formulary at HHFT and not suitable for primary care prescribing
  Nebuliser liquid
Pulmozyme (Roche Products Ltd)
  ivacaftor Non-formulary at HHFT and not suitable for primary care prescribing
  Oral tablet
Kalydeco (Vertex Pharmaceuticals (Europe) Ltd)
  ivacaftor with tezacaftor and elexacaftor NICE TA988
  Oral tablet
Kaftrio (Vertex Pharmaceuticals (Europe) Ltd)
  lumacaftor with ivacaftor Non-formulary at HHFT and not suitable for primary care prescribing NICE TA398
  Oral tablet
Orkambi (Vertex Pharmaceuticals (Europe) Ltd)
  mannitol Hospital only NICE TA266
  Infusion
Mannitol (Non-proprietary) Hospital only
  Inhalation powder
Mannitol (Non-proprietary) Hospital only
Bronchitol (Chiesi Ltd) Hospital only
  tezacaftor with ivacaftor NICE TA988
  Oral tablet
Symkevi (Vertex Pharmaceuticals (Europe) Ltd)
Respiratory system / Interstitial lung disease
  nintedanib Non-formulary at HHFT and not suitable for primary care prescribing NICE TA347
NICE TA379
NICE TA864
NICE TA747
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Oral capsule
Ofev (Boehringer Ingelheim Ltd)
Vargatef (Boehringer Ingelheim Ltd)
  pirfenidone NICE TA504
  Oral tablet
Pirfenidone (Non-proprietary)
Esbriet (Roche Products Ltd)